10-K: Mustang Bio's 10-K Filing Reveals Strategic Shift, Financial Challenges

Sentiment:

Annual Report 28 March 2025 8:02 AM

Mustang Bio's latest 10-K filing highlights a strategic focus on CAR T therapies, ongoing clinical trials, and significant financial hurdles, including substantial doubt about its ability to continue as a going concern.

Delay expectedThe company is exploring with COH and Nationwide the possibility of initiating this clinical trial as an investigator-sponsored single-institution study at COH in the fourth quarter of 2025.The company is exploring with Fred Hutch the possibility of initiating a Phase 1 trial in autoimmune diseases as an investigator-sponsored single-institution study at Fred Hutch in the fourth quarter of 2025.

Capital raiseThe company will need to raise additional financing in upcoming periods.The company completed a best-efforts public offering for net proceeds of approximately $6.9 million in February 2025.

Worse than expectedThe company has incurred significant losses and has substantial doubt about its ability to continue as a going concern.

Summary

Mustang Bio is a clinical-stage biopharmaceutical company focusing on CAR T therapies for cancer and autoimmune diseases.
The company's pipeline includes MB-109 for brain tumors and MB-106 for hematologic malignancies and autoimmune diseases.
A Phase 1 trial for MB-109 is planned as an investigator-sponsored study at City of Hope in Q4 2025.
A Phase 1 trial for MB-106 in autoimmune diseases is planned as an investigator-sponsored study at Fred Hutch in Q4 2025.
The company closed its Mustang-sponsored Phase 1/2 study in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The company has terminated license agreements for MB-102, MB-103, MB-104, MB-105, MB-117, MB-217 and MB-110.
The company has incurred significant losses since inception, with an accumulated deficit of $396.7 million as of December 31, 2024.
There is substantial doubt about the company's ability to continue as a going concern.
The company will need to raise additional financing in upcoming periods.
The company completed a 1-for-50 reverse stock split on January 15, 2025.
The company completed a best-efforts public offering for net proceeds of approximately $6.9 million in February 2025.
The company is subject to limitations on the amount of funds it can raise due to SEC regulations regarding its public float.
The company is reliant on third parties for research, development, and manufacturing.
The company is subject to intense competition in the pharmaceutical and biotechnology industries.
The company is subject to various healthcare laws and regulations.
The company is majority-controlled by Fortress Biotech, Inc., which could create conflicts of interest.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as ongoing clinical trials and partnerships, the significant financial challenges and going concern uncertainty weigh heavily on the overall sentiment.

Positives

The company is focusing on CAR T therapies, which have shown promise in treating cancers and autoimmune diseases.
The company has partnerships with reputable research institutions, including City of Hope, Fred Hutch, and Nationwide Children's Hospital.
The company has received Orphan Drug Designation for MB-108, providing certain incentives and market exclusivity.
The company completed a best-efforts public offering for net proceeds of approximately $6.9 million in February 2025.

Negatives

The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future.
There is substantial doubt about the company's ability to continue as a going concern.
The company has terminated license agreements for several product candidates.
The company is subject to limitations on the amount of funds it can raise due to SEC regulations regarding its public float.
The company is reliant on third parties for research, development, and manufacturing.
The company is subject to intense competition in the pharmaceutical and biotechnology industries.
The company is majority-controlled by Fortress Biotech, Inc., which could create conflicts of interest.

Risks

The company may not be able to obtain regulatory approval for its product candidates.
The company's product candidates may not achieve broad market acceptance.
The company may face product liability exposure.
The company may be unable to attract and retain key personnel.
The company's business could be adversely affected by health pandemics or epidemics.
The company's business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in its or third parties cybersecurity.

Future Outlook

The company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products and will need to obtain substantial additional financing.

Management Comments

Management is focused on advancing programs in hematologic cancers, autoimmune diseases and solid tumors through clinical development.
Management is exploring with COH and Nationwide the possibility of conducting an investigator-sponsored single-institution trial under the COH IND to treat patients with IL13R2+ recurrent GBM and high-grade astrocytoma with MB-109 that could potentially be initiated in the fourth quarter of 2025.
Management is exploring with Fred Hutch the possibility of initiating a Phase 1 trial in autoimmune diseases as an investigator-sponsored single-institution study at Fred Hutch in the fourth quarter of 2025.

Industry Context

The field of CAR T therapy is extremely active, with numerous companies and partnerships engaged in clinical trials. Competition in the pharmaceutical and biotechnology industries is intense.

Comparison to Industry Standards

The document mentions several competitors in the CAR T therapy field, including Bristol Myers Squibb, Novartis, AstraZeneca, Janssen Pharmaceutical Company, Legend Biotech, Gilead Sciences, Arcellx, Galapagos NV, Autolus Therapeutics, 2seventy bio, Kyverna Therapeutics, ImmPACT Bio, TG Therapeutics, and Cabaletta Bio.
These companies are engaged in clinical trials with CAR T modalities, indicating a competitive landscape for Mustang Bio.
The document does not provide specific details on how Mustang Bio's results compare to these competitors, but it highlights the company's focus on developing novel and unique drugs or methods of treatment to compete successfully.

Related Party Transactions

The company has a Founders Agreement and Management Services Agreement with Fortress Biotech, Inc.
The company issued shares of common stock to Fortress in connection with the Founders Agreement.
The company pays Fortress an annual consulting fee under the Management Services Agreement.
The company has a director compensation plan that provides cash and equity compensation to non-employee directors, including those affiliated with Fortress.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees experienced a significant workforce reduction.
Customers (patients) may benefit from successful development of new therapies, but face uncertainty due to the company's financial challenges.
Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

Initiate Phase 1 trial for MB-109 at City of Hope in Q4 2025 (potential).
Initiate Phase 1 trial for MB-106 in autoimmune diseases at Fred Hutch in Q4 2025 (potential).
Continue to seek additional funding through corporate partnerships and capital markets fundraising.

Key Dates

Date	Description
March 13, 2015	Mustang Bio, Inc. was incorporated.
March 17, 2015	Initial license agreement with City of Hope.
July 26, 2016	Second Amended and Restated Founders Agreement became effective.
April 24, 2017	Executive Employment Agreement with Dr. Litchman.
July 3, 2017	Exclusive licensing agreement with Fred Hutch for CD20 CAR T therapy.
October 27, 2017	Lease agreement for Worcester, MA facility.
February 20, 2019	Exclusive license agreement with Nationwide for MB-108.
October 2020	Clinical Research Support Agreement for IL13R2-directed CAR T program for adult patients with leptomeningeal glioblastoma.
May 2021	FDA accepted IND Application for MB-106.
June 14, 2022	Sublease agreement with The Paul Revere Life Insurance Company.
May 18, 2023	Asset Purchase Agreement with uBriGene.
July 28, 2023	Completed the sale of assets to uBriGene.
October 2023	FDA accepted IND application for MB-109.
April 10, 2024	Board approved reduction of workforce.
June 27, 2024	Asset Purchase Agreement with uBriGene to repurchase assets.
November 7, 2024	FDA granted Orphan Drug Designation to Mustang for MB-108.
January 15, 2025	1-for-50 reverse stock split.
February 10, 2025	Completed a best-efforts public offering for net proceeds of approximately $6.9 million.
February 21, 2025	Closing of the sale of equipment to AbbVie and termination of the lease.
February 26, 2025	Company was notified by the Staff that it had regained compliance with the Equity Rule and is subject to mandatory monitoring by the Panel for one year.
March 1, 2025	53 patients have been treated in an ongoing Phase 1 clinical trial sponsored by Fred Hutch (ClinicalTrials.gov Identifier: NCT03277729) and 20 patients have been treated in the Phase 1 clinical trial sponsored by us (ClinicalTrials.gov Identifier: NCT05360238).
March 26, 2025	Date of record for share information in the 10-K filing.
Q4 2025	Potential initiation of Phase 1 trial for MB-109 at City of Hope and Phase 1 trial for MB-106 in autoimmune diseases at Fred Hutch.

Keywords

CAR T therapy, glioblastoma, autoimmune diseases, clinical trials, MB-109, MB-106, biopharmaceutical, Orphan Drug Designation, Fortress Biotech, RMAT designation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.